Alnylam Pharmaceuticals reported 3 months of 2022

Alnylam Pharmaceuticals' GAAP loss for 3 months of 2022 was $240.341 million, up 20% from $200.291 million in the previous year. Revenue increased 20.1% to $213.259 million from $177.566 million a year earlier.